PRLD logo

PRLD

Profile

Full Name

Prelude Therapeutics Incorporated

Ticker Symbol

PRLD

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

September 25, 2020

Indexes

Not included

Website

http://preludetx.com

Employees

131

Key Details

Price

$0.71(+10.28%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$7.00M

Annual EPS

-$1.68(+16.83% YoY)

PE ratio

-

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.71
PRLD price is $0.71

30-Day Relative Volume

0.81
PRLD 30-day relative volume is 0.81

Price Performance

Price Most recent change

+10.28%
PRLD price was up +10.28% on Apr 11, 2025

Price YTD change

-44.47%
PRLD price is down -44.47% since January 1st

Price 1-year change

-86.44%
PRLD price is down -86.44% year-on-year

Price 3-year change

-88.65%
PRLD price is down -88.65% over the past 3 years

Price Range

Price All-time high

$95.38
PRLD price is currently -99.26% below its historical high of $95.38

Price 3-year low

$0.61
PRLD price is currently +16.07% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$39.05M
PRLD market capitalization is $39.05 million

Market cap 3-year change

-86.88%
PRLD market capitalization is down -86.88% over the past 3 years

Market cap All-time high

$4.27B
PRLD market capitalization is currently -99.09% below its historical high of $4.27 billion

Market cap sector rank

35.41%
PRLD market capitalization is higher than 35.41% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+0.42%
PRLD shares outstanding is up +0.42% year-on-year

Shares Outstanding 3-Year Change

+15.64%
PRLD shares outstanding is up +15.64% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.67
PRLD beta is 1.67

200-day SMA

$2.27
PRLD price is currently -68.86% below its 200-day simple moving average

50-day SMA

$0.81
PRLD price is currently -12.15% below its 50-day simple moving average

RSI

48.22
PRLD 14-day relative strength index is 48.22

Volume

0.81
PRLD 30-day relative volume is 0.81

ATR

$0.07
PRLD average true range is $0.07

10-day Historical Volatility

102.78%
PRLD 10-day historical volatility is 102.78%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$7.00M
PRLD annual revenue is $7.00 million

Revenue Analysts estimate

-
PRLD annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-
PRLD annual revenue 1-year change is unknown

Revenue Sector rank

23.74%
PRLD annual revenue is higher than 23.74% of companies in Healthcare sector

EPS

EPS

-$1.68
PRLD annual earnings per share is -$1.68

EPS Analysts estimate

-$1.62
PRLD annual earnings per share is currently +3.75% higher than the consensus analysts' forecast

EPS 1-year change

+16.83%
PRLD annual earnings per share is up +16.83% year-on-year

EPS Sector rank

42.11%
PRLD annual earnings per share is higher than 42.11% of companies in Healthcare sector

Profit

Gross profit

-
PRLD annual gross profit value is unknown

Gross margin

-
PRLD annual gross profit margin value is unknown

Operating profit

-$139.71M
PRLD annual operating income is -$139.71 million

Operating margin

-1995.91%
PRLD annual operating profit margin is -1995.91%

Net income

-$127.17M
PRLD annual net profit is -$127.17 million

Net margin

-1816.76%
PRLD annual net profit margin is -1816.76%

Expenses

Total expenses

$146.71M
PRLD annual total expenses is $146.71 million

Operating expenses

$146.71M
PRLD annual total operating expenses is $146.71 million

Cost of goods sold

-
PRLD annual cost of goods sold value is unknown

Selling, general & administrative expenses

$28.72M
PRLD annual SGA is $28.72 million

Depreciation and amortization

$1.77M
PRLD annual depreciation & amortization is $1.77 million

Interest expense

-
PRLD annual interest expense value is unknown

Income tax

-
PRLD annual income tax value is unknown

EBIT & EBITDA

EBIT

-$139.71M
PRLD annual earnings before interest & taxes is -$139.71 million

EBITDA

-$139.71M
PRLD annual EBITDA is -$139.71 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$175.51M
PRLD annual total assets is $175.51 million

Non current assets

$39.62M
PRLD annual long term assets is $39.62 million

Current assets

$135.90M
PRLD annual total current assets is $135.90 million

Cash and cash equivalents

$12.47M
PRLD annual cash & cash equivalents is $12.47 million

Accounts receivable

-
PRLD annual accounts receivable value is unknown

Inventory

-
PRLD annual inventory value is unknown

Liabilities

Total liabilities

$44.06M
PRLD annual total liabilities is $44.06 million

Long term liabilities

$18.41M
PRLD annual total long term liabilities is $18.41 million

Current liabilities

$25.64M
PRLD annual total current liabilities is $25.64 million

Accounts payable

$7.73M
PRLD annual accounts payable is $7.73 million

Debt

Total debt

$18.02M
PRLD annual total debt is $18.02 million

Total debt 1-year change

+6.73%
PRLD annual total debt is up +6.73% year-on-year

Long term debt

$15.32M
PRLD annual long term debt is $15.32 million

Short term debt

$2.70M
PRLD annual short term debt is $2.70 million

Equity & Capital

Shareholders equity

$131.46M
PRLD annual stockholders equity is $131.46 million

Book value

$131.46M
PRLD annual book value is $131.46 million

Retained earnings

-$583.56M
PRLD annual retained earnings is -$583.56 million

Working capital

$110.25M
PRLD annual working capital is $110.25 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$102.89M
PRLD annual cash flow from operations is -$102.89 million

Cash from operations 1-year change

+3.9%
PRLD annual cash flow from operations is up +3.9% year-on-year

Cash from investing

$90.19M
PRLD annual cash flow from investing activities is $90.19 million

Cash from investing 1-year change

+360.32%
PRLD annual cash flow from investing activities is up +360.32% year-on-year

Cash from financing

-$120.00K
PRLD annual cash flow from financing activities is -$120.00 thousand

Cash from financing 1-year change

-100.09%
PRLD annual cash flow from financing activities is down -100.09% year-on-year

CAPEX

CAPEX

$764.00K
PRLD annual capital expenditures is $764.00 thousand

CAPEX 1-year change

-
PRLD annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$103.65M
PRLD annual free cash flow is -$103.65 million

Free cash flow 1-year change

+6.26%
PRLD annual free cash flow is up +6.26% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
PRLD annual gross profit margin value is unknown

Operating margin

-1995.91%
PRLD annual operating profit margin is -1995.91%

Net margin

-1816.76%
PRLD annual net profit margin is -1816.76%

ROA & ROE

ROA

-72.46%
PRLD annual return on assets is -72.46%

ROE

-69.01%
PRLD annual return on equity is -69.01%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
PRLD price to earnings ratio value is unknown

PE ratio Sector rank

-
PRLD price to earnings ratio is unknown

PB Ratio

PB ratio

0.30
PRLD price to book ratio is 0.30

PB ratio Sector rank

23.77%
PRLD price to book ratio is higher than 23.77% of companies in Healthcare sector

PS Ratio

PS ratio

5.58
PRLD price to sales ratio is 5.58

PS ratio Sector rank

68.85%
PRLD price to sales ratio is higher than 68.85% of companies in Healthcare sector

Enterprise value

Enterprise value

$44.60M
PRLD enterprise value is $44.60 million

Enterprise value Sector rank

41.21%
PRLD enterprise value is higher than 41.21% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.32
PRLD EV/EBITDA is -0.32

EV/EBITDA Sector rank

55.34%
PRLD EV/EBITDA is higher than 55.34% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

5.30
PRLD annual current ratio is 5.30

Quick ratio

-
PRLD annual quick ratio value is unknown

Leverage

Debt to equity

0.00
PRLD annual debt to equity ratio is 0.00

Interest coverage ratio

-
PRLD annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
PRLD piotroski f-score value is unknown

Altman Z-Score

-5.96
PRLD altman z-score is -5.96

Analyst ratings

Recent major analysts updates

Apr 8, 25 HC Wainwright & Co.
Buy
Mar 12, 25 Citizens Capital Markets
Market Outperform
Dec 11, 24 JMP Securities
Market Outperform
Nov 8, 24 HC Wainwright & Co.
Buy
Oct 28, 24 HC Wainwright & Co.
Buy
Sep 19, 24 HC Wainwright & Co.
Buy
Sep 16, 24 JMP Securities
Market Outperform
Sep 16, 24 HC Wainwright & Co.
Neutral
Sep 10, 24 HC Wainwright & Co.
Neutral
Aug 15, 24 HC Wainwright & Co.
Neutral

Institutional Ownership

Similar stocks

OPGN logo
OpGen (OPGN)
MRSN logo
Mersana Therapeutics (MRSN)
TELA logo
TELA Bio (TELA)
ANTX logo
AN2 Therapeutics (ANTX)
NVNO logo
enVVeno Medical (NVNO)
ITRM logo
Iterum Therapeutics (ITRM)
DXR logo
Daxor (DXR)
RPTX logo
Repare Therapeutics (RPTX)
RANI logo
Rani Therapeutics Holdings (RANI)
  • What is the ticker symbol for Prelude Therapeutics Incorporated?
  • Does Prelude Therapeutics Incorporated pay dividends?
  • What sector is Prelude Therapeutics Incorporated in?
  • What industry is Prelude Therapeutics Incorporated in?
  • What country is Prelude Therapeutics Incorporated based in?
  • When did Prelude Therapeutics Incorporated go public?
  • Is Prelude Therapeutics Incorporated in the S&P 500?
  • Is Prelude Therapeutics Incorporated in the NASDAQ 100?
  • Is Prelude Therapeutics Incorporated in the Dow Jones?
  • When was Prelude Therapeutics Incorporated's last earnings report?
  • When does Prelude Therapeutics Incorporated report earnings?
  • Should I buy Prelude Therapeutics Incorporated stock now?

What is the ticker symbol for Prelude Therapeutics Incorporated?

The ticker symbol for Prelude Therapeutics Incorporated is NASDAQ:PRLD

Does Prelude Therapeutics Incorporated pay dividends?

No, Prelude Therapeutics Incorporated does not pay dividends

What sector is Prelude Therapeutics Incorporated in?

Prelude Therapeutics Incorporated is in the Healthcare sector

What industry is Prelude Therapeutics Incorporated in?

Prelude Therapeutics Incorporated is in the Biotechnology industry

What country is Prelude Therapeutics Incorporated based in?

Prelude Therapeutics Incorporated is headquartered in United States

When did Prelude Therapeutics Incorporated go public?

Prelude Therapeutics Incorporated's initial public offering (IPO) was on September 25, 2020

Is Prelude Therapeutics Incorporated in the S&P 500?

No, Prelude Therapeutics Incorporated is not included in the S&P 500 index

Is Prelude Therapeutics Incorporated in the NASDAQ 100?

No, Prelude Therapeutics Incorporated is not included in the NASDAQ 100 index

Is Prelude Therapeutics Incorporated in the Dow Jones?

No, Prelude Therapeutics Incorporated is not included in the Dow Jones index

When was Prelude Therapeutics Incorporated's last earnings report?

Prelude Therapeutics Incorporated's most recent earnings report was on Mar 10, 2025

When does Prelude Therapeutics Incorporated report earnings?

The next expected earnings date for Prelude Therapeutics Incorporated is May 7, 2025

Should I buy Prelude Therapeutics Incorporated stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page